ACTRN12620001101976尚未招募未知
The Pasifika Preventing Diabetes Programme: A stepped wedge cluster randomised trial investigating the effect of a lifestyle intervention involving community activation and peer support, on HbA1c levels among Pasifika people
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 3,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 4 Years 至 o limit（—）
- 性别
- All
入选标准
- •Be an adult (>=18 years) or child/adolescents (4-17 years) associated with participating churches in Greater Western and South Eastern Sydney
- •Be associated with a target church through attendance themselves or through a family member attending one of the target churches (for those who have not been attending church)
- •Churches are required to have at least 70% of their congregation from a Pasifika background
排除标准
- 未提供
研究者
相似试验
尚未招募
1 期
A phase 1, single-center, study to evaluate the safety and tolerability of a new molecule in Oral Syrup and Oral Gummy (Chewable gel) for oral use in healthy and mild to moderate COVID-19 adult human subjectsCTRI/2023/04/051726Karveer Meditech Pvt Ltd
已完成
1 期
Clinical study to check the safety and tolerability of ATRICOV 452 capsule of 500 mg in healthy adult human subjects.CTRI/2020/09/027660Atrimed Pharmaceutical Pvt Ltd24
进行中（未招募）
1 期
The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of AlemtuzumabRelapsing-remitting multiple sclerosisMedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2016-000464-42-DEGenzyme GmbH100
进行中（未招募）
1 期
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric DisordersPsychiatric DisordersMedDRA version: 20.0Level: SOCClassification code 10037175Term: Psychiatric disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: HLTClassification code 10037177Term: Infancy, childhood and adolescence psychiatric disorders NECSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-001064-30-BGACADIA Pharmaceuticals Inc.36
进行中（未招募）
1 期
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of AgeAlopecia AreataEUCTR2023-000824-12-Outside-EU/EEAPfizer, Inc.